Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.

Daniel W CoyneAjay K SinghRenato D LopesChristine K BaileyTara L DiMinoChun HuangJeffrey ConnaireAnjay RastogiSung-Gyun KimMarcelo OriasSapna ShahVickas PatelAlexander R CobitzChristoph Wanner

Published in: Clinical journal of the American Society of Nephrology : CJASN (2022)

a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.

Keyphrases

double blind
phase iii
placebo controlled
phase ii
clinical trial
chronic kidney disease
open label
study protocol
end stage renal disease
peritoneal dialysis